Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.

Autor:	Ortiz Salas PA; Servicio de Neurología, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia; Universidad del Rosario, Grupo Neuros, Bogotá, Colombia. Electronic address: portizs@cardioinfantil.org., Gaviria Carrillo M; Servicio de Neurología, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia; Universidad del Rosario, Programa de Neurología, Bogotá, Colombia., Cortés Bernal GA; Universidad del Rosario, Programa de Neurología, Bogotá, Colombia., Moreno Medina K; Departamento de Investigaciones, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia., Roa LF; Hospital Universitario Mayor, Mederi, Bogotá, Colombia., Rodríguez Quintana JH; Servicio de Neurología, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia; Universidad del Rosario, Grupo Neuros, Bogotá, Colombia; Hospital Universitario Mayor, Mederi, Bogotá, Colombia.
Jazyk:	angličtina
Zdroj:	Neurologia [Neurologia (Engl Ed)] 2023 Sep; Vol. 38 (7), pp. 504-510. Date of Electronic Publication: 2022 May 28.
DOI:	10.1016/j.nrleng.2020.08.022
Abstrakt:	Introduction: Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterised by attacks of optic neuritis and longitudinally extensive transverse myelitis. The discovery of anti-aquaporin-4 (anti-AQP4) antibodies and specific brain MRI findings as diagnostic biomarkers have enabled the recognition of a broader and more detailed clinical phenotype, known as neuromyelitis optica spectrum disorder (NMOSD). Objective: This study aimed to determine the demographic and clinical characteristics of patients with NMO/NMOSD with and without seropositivity for anti-AQP4 antibodies, in 2 quaternary-level hospitals in Bogotá. Methods: Our study included patients > 18 years of age and diagnosed with NMO/NMOSD and for whom imaging and serology results were available, assessed between 2013 and 2017 at the neurology departments of hospitals providing highly complex care. Demographic, clinical, and imaging data were gathered and compared in patients with and without seropositivity for anti-AQP4 antibodies. Results: The sample included 35 patients with NMO/NMOSD; the median age of onset was 46.5 years (P25-P75, 34.2-54.0); most patients had sensory (n = 25) and motor manifestations (n = 26), and a concomitant autoimmune disease was identified in 6. Twenty patients were seropositive for anti-AQP4 antibodies. Only age and presence of optic nerve involvement showed statistically significant differences between groups (P = .03). Conclusions: Clinical, imaging, and laboratory variables showed no major differences between patients with and without anti-AQP4 antibodies, with the exception of age of onset and presence of optic nerve involvement (uni- or bilateral); these factors should be studied in greater detail in larger populations. (Copyright © 2020 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu